Integrated Endoscopy Announces the Global Launch of Gen II Nuvis Single-Use, 4K, Battery Operated Cordless Arthroscope

Integrated Endoscopy, a medical device company pioneering the development of 4K, low-cost, single-use endoscopes for the arthroscopic surgery market, today announced the launch of its second generation NUVIS (pronounced “nu-vee”) Single-Use Arthroscope, a first-of-its-kind 4K endoscope designed for use in arthroscopic surgical procedures.

The release of the Gen II NUVIS features a patent-pending simplified optical train design that reduces the number of optical elements by over 60% while boosting image quality to 4K.  Not only is the image quality superior, but the Gen II NUVIS will also be substantially faster and less expensive to manufacture and amenable to high-volume automation.  As part of the Gen II launch, Integrated Endoscopy is releasing multiple versions of NUVIS to make the technology compatible with most cannulas on the market.  NUVIS is also compatible with most installed video towers and will support a 4K camera system without requiring additional capital equipment.  NUVIS has a built-in battery powered LED, which eliminates the light box and bulky light cord.

“The release of the Gen II NUVIS is a huge milestone for the company in terms of image quality and compatibility, said Brad Sharp, Integrated Endoscopy’s CEO. “Our nextgen arthroscope also provides a substantial decrease in manufacturing costs while simultaneously increasing ease of manufacturability. The demand we have seen for NUVIS far exceeds our current manufacturing capacity, so the efficiencies the Gen II NUVIS affords will greatly aid in shortening production time and costs.  With a global market of over 1.5 million units per month, increasing our manufacturing capacity will be a major focus for the company moving forward.”

Integrated Endoscopy’s Gen II NUVIS single-use, 4K, battery operated cordless arthroscope is FDA 501(k) cleared, CE marked, and is being registered in a number of markets around the world.  As manufacturing capacity increases, the company will continue to expand its global distribution network to provide this unique technology to the arthroscopic surgical community.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”